A prospective cohort study of asthma and COPD overlap in Japanese patients with COPD according to the diagnostic criteria of The Japanese Respiratory Society

A prospective cohort study of asthma and COPD overlap in Japanese patients with COPD according to the diagnostic criteria of The Japanese Respiratory Society - ACO Registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032891

Enrollment

700

Registered

2018-06-06

Start date

2018-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients from whom written consent to participate in this study has been obtained. 2)Patients >= 40 years old 3)Patients with the rate of forced expiratory volume in one second (FEV1/FVC) less than 70% after inhalation of a bronchodilator within the past year or at the time of registration 4)Patients who fulfill one of the following criteria: [1]Smoking history (>=10 pack-years) or equivalent air pollution exposurea at the time of registration [2]Presence of low absorption region showing emphysematous change on chest CTb, [3]Lung diffusion impairment (%DLco <80%, DLco/VA <80%) 5)Outpatients assessed as being able to visit the study site at least once a year

Exclusion criteria

Exclusion criteria: 1)Patients who participated in an intervention study such as a clinical trial within the last 8 weeks 2)Patients who is not appropriate for joining this study, judged by the investigators, due to the reasons such as they cannot comply with the procedures, restrictions and requirements of this study 3)Patients who experienced exacerbation of COPD or asthma within the last 8 weeks 4)Patients who have following diseases which cannot be distinguished from COPD or asthma at the time of obtaining consent: Diffuse panoramic bronchitis, congenital sinus bronchial syndrome, obstructive panbronchitis, bronchiectasis, pulmonary tuberculosis, pneumoconiosis, lymphangiomyomatosis, interstitial lung disease, lung cancer, vocal fold dysfunction, intratracheal tumor, tracheal softening, bronchial tuberculosis, pulmonary thromboembolism, congestive heart failure

Design outcomes

Primary

Measure	Time frame
Proportion of patients fulfilling the diagnostic criteria for ACO at the time of registration, 1 year later, and 2 years later	—

Countries

Japan

Contacts

Public ContactTatsunori Jinnai

AstraZeneca.KK. Medical

Tatsunori.Jinnai@astrazeneca.com06-7711-3714

Outcome results